We are MD Anderson
Health Care Provider Resource Center
The faculty at MD Anderson collaborates with and serves as a resource for health care providers within our community, across the nation, and around the world to provide the latest advances in cancer care.
The cancer control contiuum typically begins and ends with patients in the primary care setting that rely on the trusted relationship established with their provider. With this in mind, we continue to build upon referral access pathways to provide seamless transitions of care and deliver meaningful communication to referring providers about their patients.
By partnering with our commuities, MD Anderson is able to expand our impact on cancer through clincial trials, technology and education.
Referral Access Pathways
Patient-Centered Oncology Care and Your Practice
Cancer information developed specifically for health care providers to ensure patients are matched with the treatment options best suited for their unique cancer. Click to view or download.
Houston-Area Locations
Cancerwise Blog
Our blog features cancer research, treatment strategies and patient stories.
New understanding of why kidney cancers...
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression.
The study, published today in Nature Cancer, demonstrates that the loss of a cluster of interferon receptor (IFNR) genes plays a pivotal role in allowing cancer cells to become tolerant of...
Antibody drug conjugates: A shift in...
Antibody drug conjugates have existed for years, but several recent advances are helping to refine how these cancer drugs work, expanding our understanding to help overcome their challenges and, ultimately, extending their benefit to more patients.
“Antibody drug conjugates are an exciting field of drug development,” says Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics.
Antibody drug conjugates target cancer...
Clinical trial of new AhR inhibitor shows...
The human immune system is constantly attacking damaged cells that might turn into cancer, thus protecting us from these cells growing out of control and becoming malignant. However, cancer cells have many ways of protecting themselves from the body’s immune system. One of these is a protein, called aryl hydrocarbon receptor (AhR), which is common on tumor and immune cells. When AhR is activated, it causes immunosuppression and...